Search company, investor...


Founded Year



Acquired | Acquired

Total Raised




About FlowCardia

FlowCardia, Inc. is a medical device company founded in March 2002 to design and develop High Frequency Mechanical Recanalization (HFMR) devices intended to cross totally occluded arteries. Chronic Total Occlusions (CTOs) are considered the last frontier in interventional cardiology and the absence of effective devices to recanalize calcified CTOs is a major reason that cardiologists still refer a large number of patients to coronary artery bypass graft surgery (CABG). It is estimated that over 20% of all interventional cardiology procedures involve CTOs. Half of these cases are crossable with conventional guidewires. The other half consume considerable physician time manipulating standard coronary guidewires and many end up uncrossable despite all efforts.

Headquarters Location

745 North Pastoria Avenue

Sunnyvale, California, 94085,

United States


Missing: FlowCardia's Product Demo & Case Studies

Promote your product offering to tech buyers.

Reach 1000s of buyers who use CB Insights to identify vendors, demo products, and make purchasing decisions.

Missing: FlowCardia's Product & Differentiators

Don’t let your products get skipped. Buyers use our vendor rankings to shortlist companies and drive requests for proposals (RFPs).

FlowCardia Patents

FlowCardia has filed 1 patent.

The 3 most popular patent topics include:

  • Medical equipment
  • Medical ultrasonography
  • Interventional radiology
patents chart

Application Date

Grant Date


Related Topics




Medical ultrasonography, Medical equipment, Ultrasound, Vascular procedures, Catheters


Application Date


Grant Date



Related Topics

Medical ultrasonography, Medical equipment, Ultrasound, Vascular procedures, Catheters



Latest FlowCardia News

Medical ResearchViews – C. R. Bard Completes Acquisition Of FlowCardia For US$80.1 Million

Jul 9, 2013

C. R. Bard Completes Acquisition Of FlowCardia For US$80.1 Million Published: Apr 12 2010 Deal Summary C. R. Bard, Inc., a medical technology company, completed the acquisition of FlowCardia, Inc., a developer of endovascular devices for coronary and peripheral chronic total occlusion (CTO) recanalization. The transaction is valued at approximately $80.1m. The investors of FlowCardia include Gilde Healthcare Partners B.V., Life Sciences Partners, Hambrecht & Quist Capital Management, LLC, New Science Ventures, Rockport Venture Partners, Gold Hill Capital Management, LLC, Frazier Healthcare Ventures, J.P. Morgan Partners, LLC and Pappas Ventures. “The products my team developed at FlowCardia for crossing chronic total occlusions or CTOs represent an important advancement in managing lower limb arterial disease. I believe this is a real complement to Bard’s PTA products and their peripheral vascular stents.” said Wick Goodspeed, former CEO of FlowCardia. FlowCardia's CROSSERTM CTO recanalization catheter, steerable support catheters, and porter guidewires comprise a family of tools which enable physicians to cross chronic total occlusions allowing for subsequent balloon angioplasty, atherectomy, and/or stent placement. Weil, Gotshal & Manges LLP served as legal counsel to C. R. Bard on the transaction. Send to friend

FlowCardia Frequently Asked Questions (FAQ)

  • When was FlowCardia founded?

    FlowCardia was founded in 2001.

  • Where is FlowCardia's headquarters?

    FlowCardia's headquarters is located at 745 North Pastoria Avenue, Sunnyvale.

  • What is FlowCardia's latest funding round?

    FlowCardia's latest funding round is Acquired.

  • How much did FlowCardia raise?

    FlowCardia raised a total of $30M.

  • Who are the investors of FlowCardia?

    Investors of FlowCardia include C.R. Bard, Frazier Healthcare Partners, J.P. Morgan Chase & Co., New Science Ventures, Tekla Capital Management and 8 more.

  • Who are FlowCardia's competitors?

    Competitors of FlowCardia include NeoChord, Reva Medical, ALung Technologies, Ivenix, Broncus Medical, Tepha, Cardiva Medical, Relievant Medsystems, OrthAlign, Mimedx and 49 more.

Compare FlowCardia to Competitors

NeoChord Logo

NeoChord is a medical technology company engaged in the advancement of beating heart mitral valve repair in patients suffering from mitral valve regurgitation. The company's flagship product, the NeoChord Artificial Chordae Delivery System, is a beating heart procedure, echo-guided treatment for patients with mitral valve regurgitation and is proven to resolve and restore normal mitral valve function. The company was founded in 2007 and is based in Minneapolis, Minnesota.

Es Vascular

ES Vascular Ltd. developed first ever surgical stapling devices for endovascular surgery. These devices aim to transform vascular surgery by shortening procedural times, and by simplifying and potentially increasing the safety of the most common vascular interventions. The company is currently developing three product lines for open AAA, endovascular AAA and Femoro-Pop bypass procedures. Its first products are anticipated to enter the market in 2008.nCompany Snapshotn Started in 2000 in Israel by Prof. Shifrin together with group of engineers and leading vascular surgeons from the US and Europe;n Developed a ever vascular stapling technology for stapling synthetic grafts to the aortan Developed endovascular devices for EVAR and SFA procedures


CoRepair, Inc. is developing a radiofrequency (RF) device system for the treatment of congestive heart failure.

InfraReDx Logo

InfraReDx is a medical device company dedicated to helping provide practitioners with the information needed for enhanced clinical decision making in treating coronary artery disease. The company is committed to improving the safety and efficacy of coronary stenting and ultimately serving as part of a strategy to prevent initial coronary events. Through its TVC Imaging System, InfraReDx is changing the way coronary artery disease is diagnosed and treated. The TVC Imaging System is the only intravascular imaging system that enables true vessel characterization through simultaneous structural and compositional imaging data obtained in a single pullback.

Reva Medical

REVA Medical develops interventional medical devices that leverage the company's stent designs and biomaterials to improve the treatment of vascular disease. Its flagship product is called MOTIV, a bioresorbable coronary stent that is designed to fulfill the temporary need for a stent and then fade away, leaving only the healed vessel behind. This product is utilized for the treatment of coronary artery disease. REVA Medical has a broad strategic relationship with Boston Scientific Corporation, a worldwide developer and marketer of interventional medical devices. The company was founded in 1998 and is based in San Diego, California.

Monterey Devices

Stealth mode medical device company developing devices for drug delivery. Monterey Devices submitted a patent on device for buffering anesthetics.

Discover the right solution for your team

The CB Insights tech market intelligence platform analyzes millions of data points on vendors, products, partnerships, and patents to help your team find their next technology solution.

Request a demo

CBI websites generally use certain cookies to enable better interactions with our sites and services. Use of these cookies, which may be stored on your device, permits us to improve and customize your experience. You can read more about your cookie choices at our privacy policy here. By continuing to use this site you are consenting to these choices.